{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:42:13Z","timestamp":1791049333787,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry &amp; Cell Biology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.biocel.2005.08.006","type":"journal-article","created":{"date-parts":[[2005,9,10]],"date-time":"2005-09-10T08:17:54Z","timestamp":1126340274000},"page":"766-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-\u03b3"],"prefix":"10.1016","volume":"38","author":[{"given":"Harrihar A.","family":"Pershadsingh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biocel.2005.08.006_bib1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cardiores.2004.12.008","article-title":"Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock","volume":"65","author":"Abdelrahman","year":"2005","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.biocel.2005.08.006_bib2","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1126\/science.1056843","article-title":"Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2","volume":"291","author":"Abu-Elheiga","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biocel.2005.08.006_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0895-7061(02)03197-7","article-title":"Decreased plasma adiponectin concentration in patients with essential hypertension","volume":"16","author":"Adamczak","year":"2003","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2337\/diabetes.51.4.1042","article-title":"Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation","volume":"51","author":"Albrektsen","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.biocel.2005.08.006_bib6","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.27.2007.S5","article-title":"Diagnosis and Classification of Diabetes Mellitus","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib7","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI115260","article-title":"Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans","volume":"87","author":"Anderson","year":"1991","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.biocel.2005.08.006_bib8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1161\/01.CIR.0000018622.84402.FF","article-title":"Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell","volume":"105","author":"Arita","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","article-title":"Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity","volume":"257","author":"Arita","year":"1999","journal-title":"Biochemical and Biophysical Research Communication"},{"key":"10.1016\/j.biocel.2005.08.006_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjp.0702818","article-title":"Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells","volume":"128","author":"Asano","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.biocel.2005.08.006_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2005.03.003","article-title":"PPARs: Therapeutic targets for metabolic disease","volume":"26","author":"Berger","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.biocel.2005.08.006_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/me.2002-0217","article-title":"Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator","volume":"17","author":"Berger","year":"2003","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.biocel.2005.08.006_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0960-0760(03)00214-0","article-title":"Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation","volume":"85","author":"Blanquart","year":"2003","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.biocel.2005.08.006_bib16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1185\/030079904X3861","article-title":"The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: An observational study in 16600 patients in primary care","volume":"20","author":"Bramlage","year":"2004","journal-title":"Current Medical Research Opinion"},{"key":"10.1016\/j.biocel.2005.08.006_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ecl.2004.03.005","article-title":"The metabolic syndrome: Prevalence in worldwide populations","volume":"33","author":"Cameron","year":"2004","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1016\/j.biocel.2005.08.006_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diabetes.49.4.539","article-title":"Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone","volume":"49","author":"Camp","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.biocel.2005.08.006_bib19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.CIR.100.8.820","article-title":"Insulin stimulates both endothelin and nitric oxide activity in the human forearm","volume":"100","author":"Cardillo","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","article-title":"PPAR{gamma}-activating angiotensin type-1 receptor blockers induce adiponectin","volume":"46","author":"Clasen","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib21","series-title":"The PPAR\u03b3-activating ARB irbesartan stimulates expression of the insulin-signaling protein CAP and enhances insulin-induced glucose uptake","author":"Clemenz","year":"2004"},{"key":"10.1016\/j.biocel.2005.08.006_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.embor.7400082","article-title":"Peroxisome proliferator-activated receptor-gamma: Too much of a good thing causes harm","volume":"5","author":"Cock","year":"2004","journal-title":"EMBO Reports"},{"key":"10.1016\/j.biocel.2005.08.006_bib23","doi-asserted-by":"crossref","first-page":"18365","DOI":"10.1074\/jbc.273.29.18365","article-title":"Altered cell surface expression and signaling of leptin receptors containing the fatty mutation","volume":"273","author":"Crouse","year":"1998","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biocel.2005.08.006_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International Union of Pharmacology XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.biocel.2005.08.006_bib26","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","volume":"26","author":"Derosa","year":"2004","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.biocel.2005.08.006_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1291\/hypres.27.457","article-title":"Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study","volume":"27","author":"Derosa","year":"2004","journal-title":"Hypertension Research"},{"key":"10.1016\/j.biocel.2005.08.006_bib29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biocel.2005.08.006_bib30","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/diacare.27.10.2444","article-title":"Increasing prevalence of the metabolic syndrome among U.S. adults","volume":"27","author":"Ford","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.febslet.2004.09.027","article-title":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes","volume":"576","author":"Fujimoto","year":"2004","journal-title":"FEBS Letters"},{"key":"10.1016\/j.biocel.2005.08.006_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2169\/internalmedicine.38.202","article-title":"Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity","volume":"38","author":"Funahashi","year":"1999","journal-title":"Internal Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib33","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1210\/endo.143.6.8842","article-title":"Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"143","author":"Gerhold","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.biocel.2005.08.006_bib34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.biocel.2005.08.006_bib35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","article-title":"Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study","volume":"21","author":"Grassi","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib36","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2004-0372","article-title":"Obesity metabolic syndrome, and cardiovascular disease","volume":"89","author":"Grundy","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.biocel.2005.08.006_bib37","first-page":"283","article-title":"Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome","volume":"5","author":"Harwood","year":"2004","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.biocel.2005.08.006_bib38","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/hy1101.092970","article-title":"Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats","volume":"38","author":"Henriksen","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000081070","article-title":"Novel PPARgamma agonists GI262570, GW 7845 GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries","volume":"73","author":"Heppner","year":"1929","journal-title":"Pharmacology"},{"key":"10.1016\/j.biocel.2005.08.006_bib40","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.amjmed.2003.09.018","article-title":"Considerations for management of fluid dynamic issues associated with thiazolidinediones","volume":"115","author":"Hollenberg","year":"2003","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/diacare.28.2.498","article-title":"Possible beneficial effect of telmisartan on glycemic control in diabetic subjects","volume":"28","author":"Honjo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.biocel.2005.08.006_bib43","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","article-title":"Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients","volume":"20","author":"Hotta","year":"2000","journal-title":"Arteriosclerosis, Thrombosis and Vascular Biology"},{"key":"10.1016\/j.biocel.2005.08.006_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/01.CIR.0000140762.04598.F9","article-title":"National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study","volume":"110","author":"Hunt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib45","unstructured":"International Diabetes Federation consensus worldwide definition of the metabolic syndrome, 14 April 2005: www.idf.org\/webdata\/docs\/Metac_syndrome_def.pdf."},{"key":"10.1016\/j.biocel.2005.08.006_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2005.08.006_bib47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1172\/JCI10830","article-title":"Insights into insulin resistance and type 2 diabetes from knockout mouse models","volume":"106","author":"Kadowaki","year":"2000","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.biocel.2005.08.006_bib48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/diacare.25.6.971","article-title":"Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure","volume":"25","author":"Kazumi","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib49","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","article-title":"Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes","volume":"51","author":"Kelley","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.biocel.2005.08.006_bib50","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI117899","article-title":"The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase","volume":"95","author":"Kern","year":"1995","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.biocel.2005.08.006_bib51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2004.09.012","article-title":"Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma","volume":"115","author":"Kojima","year":"2005","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.biocel.2005.08.006_bib52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","article-title":"PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance","volume":"4","author":"Kubota","year":"1999","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2005.08.006_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/01.ATV.0000048856.22331.50","article-title":"Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men","volume":"23","author":"Kumada","year":"2003","journal-title":"Arteriosclerosis, Thrombosis and Vascular Biology"},{"key":"10.1016\/j.biocel.2005.08.006_bib54","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib55","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwf145","article-title":"Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study","volume":"156","author":"Laaksonen","year":"2002","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.biocel.2005.08.006_bib56","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.biocel.2005.08.006_bib57","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib58","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib59","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib60","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3109\/10641969909070849","article-title":"Long-term safety and antihypertensive efficacy of irbesartan: Pooled results of five open-label studies","volume":"21","author":"Littlejohn","year":"1999","journal-title":"Clinical Experimental Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00005344-200207000-00014","article-title":"Pharmacokinetics of irbesartan are not altered in special populations","volume":"40","author":"Marino","year":"2002","journal-title":"Journal Cardiovascular Pharmacology"},{"key":"10.1016\/j.biocel.2005.08.006_bib62","doi-asserted-by":"crossref","first-page":"37487","DOI":"10.1074\/jbc.M206083200","article-title":"Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis","volume":"277","author":"Matsuda","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1749-6632.1999.tb07793.x","article-title":"Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances","volume":"892","author":"Matsuzawa","year":"1999","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.biocel.2005.08.006_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosissup.2005.02.003","article-title":"Adiponect Identification physiology clinical relevance in metabolic and vascular disease","volume":"6","author":"Matsuzawa","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biocel.2005.08.006_bib65","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1210\/endo.143.7.8892","article-title":"Minireview: Nuclear receptor coactivators-an update","volume":"143","author":"McKenna","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.biocel.2005.08.006_bib66","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.biocel.2005.08.006_bib67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11886-002-0110-9","article-title":"Vasodilatory edema: A common side effect of antihypertensive therapy","volume":"4","author":"Messerli","year":"2002","journal-title":"Current Cardiology Reports"},{"key":"10.1016\/j.biocel.2005.08.006_bib68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002018-200427050-00005","article-title":"Safety of telmisartan in patients with arterial hypertension: An open-label observational study","volume":"27","author":"Michel","year":"2004","journal-title":"Drug Safety"},{"key":"10.1016\/j.biocel.2005.08.006_bib69","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1517\/13543784.12.9.1489","article-title":"Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome","volume":"12","author":"Miller","year":"2003","journal-title":"Expert Opinion in Investigational Drugs"},{"key":"10.1016\/j.biocel.2005.08.006_bib70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/01.HYP.0000022806.87281.62","article-title":"Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance","volume":"40","author":"Miller","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2337\/diacare.28.3.757","article-title":"Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences","volume":"28","author":"Miura","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib72","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1210\/jc.2004-0190","article-title":"Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients","volume":"89","author":"Miyazaki","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.biocel.2005.08.006_bib73","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/414821a","article-title":"New drug targets for Type 2 diabetes and the metabolic syndrome","volume":"414","author":"Moller","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2005.08.006_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.med.56.082103.104751","article-title":"Metabolic syndrome: A clinical and molecular perspective","volume":"56","author":"Moller","year":"2005","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib75","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocrinology Practice"},{"key":"10.1016\/j.biocel.2005.08.006_bib76","doi-asserted-by":"crossref","unstructured":"NCEP\/ATP III: Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2001). Journal of the American Medical Association, 285, 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.biocel.2005.08.006_bib77","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib78","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1073\/pnas.96.11.6102","article-title":"A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation","volume":"96","author":"Oberfield","year":"1999","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1016\/j.biocel.2005.08.006_bib79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI10843","article-title":"Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists","volume":"106","author":"Olefsky","year":"2000","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.biocel.2005.08.006_bib80","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.CIR.0000055188.83694.B3","article-title":"Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue","volume":"107","author":"Ouchi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00041433-200312000-00003","article-title":"Obesity, adiponectin and vascular inflammatory disease","volume":"14","author":"Ouchi","year":"2003","journal-title":"Current Opinion in Lipidology"},{"issue":"Suppl. 3","key":"10.1016\/j.biocel.2005.08.006_bib82","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/sj.jhh.1001437","article-title":"The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis","volume":"16","author":"Papademetriou","year":"2002","journal-title":"Journal of Human Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archinte.163.4.427","article-title":"The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey 1988\u20131994","volume":"163","author":"Park","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.biocel.2005.08.006_bib84","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1517\/13543784.8.11.1859","article-title":"Pharmacological peroxisome proliferator-activated receptorgamma ligands: Emerging clinical indications beyond diabetes","volume":"8","author":"Pershadsingh","year":"1999","journal-title":"Expert Opinion in Investigational Drugs"},{"key":"10.1016\/j.biocel.2005.08.006_bib85","unstructured":"Pershadsingh, H.A. (2003). Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure. United States Patent Application 20040127443, patent pending."},{"key":"10.1016\/j.biocel.2005.08.006_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/13543784.13.3.215","article-title":"Peroxisome proliferator-activated receptor-gamma: Therapeutic target for diseases beyond diabetes: Quo vadis?","volume":"13","author":"Pershadsingh","year":"2004","journal-title":"Expert Opinion in Investigational Drugs"},{"key":"10.1016\/j.biocel.2005.08.006_bib87","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2337\/diacare.27.4.1015","article-title":"Insulin-sensitizing effects of telmisartan: Implications for treating insulin-resistant hypertension and cardiovascular disease","volume":"27","author":"Pershadsingh","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib88","series-title":"Symposium on the Role of Nuclear Receptors in Cardiovascular Disease","first-page":"29","article-title":"Identification of PPAR-gamma Activators That Do Not Promote Fluid Retention and Edema: Implications for Treating Insulin Resistant Hypertension and the Metabolic Syndrome","author":"Pershadsingh","year":"2003"},{"key":"10.1016\/j.biocel.2005.08.006_bib89","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/01.HYP.21.6.1020","article-title":"Effects of ciglitazone on blood pressure and intracellular calcium metabolism","volume":"21","author":"Pershadsingh","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.biocel.2005.08.006_bib90","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(99)00379-4","article-title":"Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: Comparison with subjects with insulin resistance syndrome and normal controls","volume":"34","author":"Piatti","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.biocel.2005.08.006_bib91","unstructured":"Prescribing information (2005) Actos\u00ae (pioglitazone hydrochloride) Tablets, Takeda Chemical Industries Ltd, Osaka, Japan."},{"key":"10.1016\/j.biocel.2005.08.006_bib92","unstructured":"Prescribing information (2005) Avandia\u00ae (rosiglitazone maleate) Tablets, SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA."},{"key":"10.1016\/j.biocel.2005.08.006_bib93","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture: Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.biocel.2005.08.006_bib94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2005.08.006_bib95","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1161\/01.CIR.0000132467.45278.59","article-title":"Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?","volume":"109","author":"Ridker","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00041433-200312000-00004","article-title":"Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: Current evidence and future directions","volume":"14","author":"Roberts","year":"2003","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.biocel.2005.08.006_bib97","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.exer.2004.10.009","article-title":"Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand","volume":"80","author":"Sarayba","year":"2005","journal-title":"Experimental Eye Research"},{"key":"10.1016\/j.biocel.2005.08.006_bib98","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/bbrc.1998.0126","article-title":"Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARgamma on vascular endothelial function","volume":"254","author":"Satoh","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.biocel.2005.08.006_bib99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1262-3636(07)70146-5","article-title":"Renin-angiotensin inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials","volume":"30","author":"Scheen","year":"2004","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.biocel.2005.08.006_bib100","series-title":"Proceedings of the Third International Symposium on PPAR Efficacy and Safety","first-page":"11","article-title":"PPAR\u03b3 activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes","author":"Schupp","year":"2005"},{"key":"10.1016\/j.biocel.2005.08.006_bib101","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib102","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","article-title":"C-reactive protein and the risk of developing hypertension.","volume":"290","author":"Sesso","year":"2003","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.biocel.2005.08.006_bib103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/0929867033368295","article-title":"Recent advances in peroxisome proliferator-activated receptor science","volume":"10","author":"Shearer","year":"2003","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib104","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/0091270003257230","article-title":"Ragaglitazar: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes","volume":"43","author":"Skrumsager","year":"2003","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.biocel.2005.08.006_bib105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-9255-1-3","article-title":"Cancer, inflammation and the AT1 and AT2 receptors","volume":"1","author":"Smith","year":"2004","journal-title":"Journal of Inflammation (London)"},{"key":"10.1016\/j.biocel.2005.08.006_bib106","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/009127000004001202","article-title":"Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.biocel.2005.08.006_bib107","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"International Journal of Biochem istry and Cell Biology"},{"key":"10.1016\/j.biocel.2005.08.006_bib108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1358\/dnp.2003.16.2.740244","article-title":"Modulation of vascular inflammation by PPARs","volume":"16","author":"Tham","year":"2003","journal-title":"Drug News Perspective"},{"key":"10.1016\/j.biocel.2005.08.006_bib109","doi-asserted-by":"crossref","first-page":"18785","DOI":"10.1074\/jbc.M206999200","article-title":"Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells","volume":"278","author":"Tordjman","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1590\/S0100-879X2002000900001","article-title":"Recent advances in angiotensin II signaling","volume":"35","author":"Touyz","year":"2002","journal-title":"Brazilian Journal of medical Biological Research"},{"key":"10.1016\/j.biocel.2005.08.006_bib111","doi-asserted-by":"crossref","unstructured":"Vidal, J., Morinigo, R., Codoceo, V.H., Casamitjana, R., Pellitero, S., & Gomis, R. (2005). The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. International Journal of Obesity and Related Metabolic Disorders, March 8 [Epub ahead of print].","DOI":"10.1038\/sj.ijo.0802921"},{"key":"10.1016\/j.biocel.2005.08.006_bib112","doi-asserted-by":"crossref","unstructured":"Vitale, C., Mercuro, G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., et al. (2005). Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology, 4, 6 (8 p.).","DOI":"10.1186\/1475-2840-4-6"},{"key":"10.1016\/j.biocel.2005.08.006_bib113","first-page":"330","article-title":"Incidence of pedal edema formation with dihydropyridine calcium channel blockers: Issues and practical significance","volume":"5","author":"Weir","year":"2003","journal-title":"Journal of Clinical Hypertension (Greenwich)"},{"key":"10.1016\/j.biocel.2005.08.006_bib114","series-title":"Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1. Diagnosis and Classification of Diabetes Mellitus","first-page":"1","year":"1999"},{"key":"10.1016\/j.biocel.2005.08.006_bib115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: From orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib116","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/cs1030137","article-title":"Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population","volume":"103","author":"Yamamoto","year":"2002","journal-title":"Clinical Sciences (London)"},{"key":"10.1016\/j.biocel.2005.08.006_bib118","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M103241200","article-title":"The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance","volume":"276","author":"Yamauchi","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib119","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biocel.2005.08.006_bib120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.CIR.0000140125.26161.49","article-title":"American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke. Group I. Worldwide demographics of obesity","volume":"110","author":"York","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biocel.2005.08.006_bib121","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1074\/jbc.M409468200","article-title":"The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis","volume":"280","author":"Yu","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2005.08.006_bib122","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802496","article-title":"Adipose tissue, insulin action and vascular disease: Inflammatory signals","volume":"27","author":"Yudkin","year":"2003","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1016\/j.biocel.2005.08.006_bib123","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"}],"container-title":["The International Journal of Biochemistry &amp; Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272505002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272505002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:22:57Z","timestamp":1761200577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272505002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":123,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1357272505002529"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2005.08.006","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-\u03b3","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2005.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}